ORION-8: one step closer to understanding the safety and efficacy of inclisiran
- PMID: 39082271
- DOI: 10.1093/cvr/cvae166
ORION-8: one step closer to understanding the safety and efficacy of inclisiran
Conflict of interest statement
Conflict of interest: G.D.N. reports grants from Amgen, Novartis, and Pfizer; consultant to Amarin, MSD, and Viatris. L.T. reports honoraria or consulting fees from Abbott, Amgen, AstraZeneca, Bayer, Daiichi Sankyo, Lilly, MSD, Novartis, Novo Nordisk, Sanofi, Pfizer, and Ultragenyx.
Comment on
-
Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial.Cardiovasc Res. 2024 Oct 14;120(12):1400-1410. doi: 10.1093/cvr/cvae109. Cardiovasc Res. 2024. PMID: 38753448 Free PMC article. Clinical Trial.